TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34175978

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 41
Study: 33652233

Group type: EXPERIMENTAL
Intervention: Core stability exercises
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Task oriented trainings
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional balance exercise program (Control Group)
Number of subjects: 45
Study: 32809271

Group type: EXPERIMENTAL
Intervention: Fenfluramine (0.2 mg/kg/day, titrated to a maximum of 0.7 mg/kg/day or 0.4 mg/kg/day with stiripentol)
Number of subjects: 232
Study: 33838113

Group type: EXPERIMENTAL
Intervention: Voxelotor 1500 mg
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Voxelotor 900 mg
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 35258154

Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg (early cladribine)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Cladribine tablets 3.5 mg/kg (delayed cladribine)
Number of subjects: 342
Study: 32131849

Group type: EXPERIMENTAL
Intervention: EuroFIT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 34533461

Group type: EXPERIMENTAL
Intervention: Real-time remote consultations using secure videoconferencing software
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard face-to-face appointments (usual care)
Number of subjects: 54
Study: 32385506

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 18107

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 18107

Group type: COMPARATOR
Intervention: SBP <110 mmHg
Number of subjects: 18107

Group type: COMPARATOR
Intervention: SBP 140-160 mmHg
Number of subjects: 18107

Group type: COMPARATOR
Intervention: SBP ≥160 mmHg
Number of subjects: 18107

Group type: COMPARATOR
Intervention: DBP <70 mmHg
Number of subjects: 18107

Group type: COMPARATOR
Intervention: DBP >90 mmHg
Number of subjects: 18107

Group type: COMPARATOR
Intervention: DBP 80-<90 mmHg
Number of subjects: 18107
Study: 33145992

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic-assisted anorectal pull-through (LAARP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2D laparoscopic-assisted anorectal pull-through (LAARP)
Number of subjects: 40
Study: 36113442

Group type: EXPERIMENTAL
Intervention: Educational intervention (1-hour information session and video viewing on ageism)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (1 hour of videos unrelated to ageism)
Number of subjects: 56
Study: 34137548

Group type: EXPERIMENTAL
Intervention: Triple combination cream and oral tranexamic acid
Number of subjects: 63

Group type: COMPARATOR
Intervention: Triple combination cream alone
Number of subjects: 63
Study: 32597122

Group type: EXPERIMENTAL
Intervention: 20 Watt laser device
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 Watt laser device (below 20 Watt power)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 Watt laser device (over 20 Watt power)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 33307111

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337

Group type: COMPARATOR
Intervention: Reference group (small or closed ductus)
Number of subjects: 337
Study: 615705383

Group type: EXPERIMENTAL
Intervention: Clinical Guidance (CG) provided through virtual patient simulation
Number of subjects: 103
Study: 36169032

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 459
Study: 34214499

Group type: EXPERIMENTAL
Intervention: NU‐FlexSIV Socket
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ischial Containment (IC) Socket
Number of subjects: 30
Study: 35901377

Group type: EXPERIMENTAL
Intervention: PSYCHOPATHY.COMP
Number of subjects: 119

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 119
Study: 33831896

Group type: EXPERIMENTAL
Intervention: REx (1 set to failure of 12 exercises)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AEx (walking at 65%‐70% heart rate max for 45 min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SED (sedentary control)
Number of subjects: 24
Study: 32334510

Group type: EXPERIMENTAL
Intervention: 0.5 μg·kg-1 DEX infusion (n=24)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 1.0 μg·kg-1 DEX infusion (n=25)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (saline infusion, n=24)
Number of subjects: 73
Study: 35961362

Group type: EXPERIMENTAL
Intervention: RotaTeq (3 doses at 6, 10, and 14 weeks)
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Rotarix (2 doses at 6 and 10 weeks)
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: RotaTeq (2 doses at 6 and 10 weeks)
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: RotaTeq (3 doses)
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Rotarix (2 doses)
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: RotaTeq and Rotarix
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: RotaTeq
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Rotarix
Number of subjects: 1144
Study: 33687531

Group type: EXPERIMENTAL
Intervention: Passive static stretching training (PST) for plantarflexor muscles (5×45 s-on/15 s-off)×2 exercises, 5 times/week for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no PST)
Number of subjects: 30
Study: 32304486

Group type: EXPERIMENTAL
Intervention: IOL exchange with retropupillary fixation of an iris-claw IOL (n = 44 for ECD measurement)
Number of subjects: 104

Group type: COMPARATOR
Intervention: IOL repositioning by scleral suturing (n = 50 for ECD measurement)
Number of subjects: 104
Study: 33462302

Group type: EXPERIMENTAL
Intervention: HDP
Number of subjects: 4584
Study: 32491276

Group type: EXPERIMENTAL
Intervention: TAPVC group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Hypoplastic left heart syndrome, endocardial cushion defect, conotruncal defect groups
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ventricular septal defect group
Number of subjects: 69
Study: 35775313

Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy plus trastuzumab
Number of subjects: 0
Study: 34027637

Group type: EXPERIMENTAL
Intervention: 1:1 I:E ratio ventilation
Number of subjects: 48

Group type: COMPARATOR
Intervention: 1:2 I:E ratio ventilation
Number of subjects: 48
Study: 32233747

Group type: EXPERIMENTAL
Intervention: Opioid users (OU)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Alcohol and other drug users (AOD)
Number of subjects: 506
Study: 35701752

Group type: EXPERIMENTAL
Intervention: Cognitive rehearsal program delivered in five two-hour sessions over three weeks.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group received only written information about incivility.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cognitive rehearsal program
Number of subjects: 80
Study: 33411058

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 102
Study: 34546436

Group type: EXPERIMENTAL
Intervention: Undermining (2 cm)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-undermined
Number of subjects: 50
Study: 32895345

Group type: EXPERIMENTAL
Intervention: Life Respect Enhancement Program
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 35253265

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-based inference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-assisted inference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-based estimators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-assisted estimators
Number of subjects: 0
Study: 34425533

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) alone
Number of subjects: 228
Study: 33238730

Group type: EXPERIMENTAL
Intervention: Positive social and care interactions
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Care-related interactions
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: One-on-one interactions
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Interactions with nursing staff
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Interactions with support staff
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Close interpersonal distance
Number of subjects: 379
Study: 32065856

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pralatrexate
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Romidepsin
Number of subjects: 92
Study: 36045426

Group type: EXPERIMENTAL
Intervention: prednisolone plus colchicine
Number of subjects: 67

Group type: COMPARATOR
Intervention: prednisolone plus cimetidine
Number of subjects: 67
Study: 34868330

Group type: EXPERIMENTAL
Intervention: Maxing Xianchang Su
Number of subjects: 206

Group type: COMPARATOR
Intervention: Lactulose oral solution
Number of subjects: 206
Study: 35291694

Group type: EXPERIMENTAL
Intervention: IV alpha-1 antitrypsin (AAT) 120 mg/kg weekly
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IV alpha-1 antitrypsin (AAT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 34967397

Group type: EXPERIMENTAL
Intervention: Vedolizumab (VDZ)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 419
Study: 34029730

Group type: EXPERIMENTAL
Intervention: Big Stick Design (BSD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Permuted Block Design (PBD)
Number of subjects: 0
Study: 32295780

Group type: EXPERIMENTAL
Intervention: Usual care plus the structured transition programme
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study: 36307862

Group type: EXPERIMENTAL
Intervention: STARC-SUD (Skills Training in Affect Regulation – a Culture-sensitive approach)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 286
Study: 33221910

Group type: EXPERIMENTAL
Intervention: Integrated CBTI with PAP adherence program
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sleep education control sessions
Number of subjects: 125
Study: 32030488

Group type: EXPERIMENTAL
Intervention: p48MW HPC flow diverter with SAPT
Number of subjects: 8
Study: 34631601

Group type: EXPERIMENTAL
Intervention: Standard treatment with emollients and topical corticosteroids plus dilute bleach baths (DBB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard treatment with emollients and topical corticosteroids
Number of subjects: 28
Study: 32318749

Group type: EXPERIMENTAL
Intervention: Intrathecal dexmedetomidine (5 μg, added to local anesthetics)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (1 μg/kg infused during 10 min before blockade)
Number of subjects: 50
Study: 36245293

Group type: EXPERIMENTAL
Intervention: Ozone gas
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1% chlorhexidine (CHX) gel
Number of subjects: 30
Study: 32075834

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 35673524

Group type: EXPERIMENTAL
Intervention: AMI Choice conversation tool
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study: 35266342

Group type: EXPERIMENTAL
Intervention: Discontinuation of inappropriate medications
Number of subjects: 2000
Study: 32464216

Group type: EXPERIMENTAL
Intervention: Novel trial strategies including comprehensive consumer engagement, core outcome sets, novel trial designs, streamlined data collection, cost-effectiveness evaluations, knowledge dissemination plans, and impact evaluation.
Number of subjects: 0
Study: 35819327

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase added to EVT
Number of subjects: 633

Group type: COMPARATOR
Intervention: EVT alone
Number of subjects: 633
Study: 33200844

Group type: EXPERIMENTAL
Intervention: BCG-PSN
Number of subjects: 120

Group type: COMPARATOR
Intervention: BCG vaccine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120
Study: 36384392

Group type: EXPERIMENTAL
Intervention: Biopsy during emergency gastroscopy
Number of subjects: 150

Group type: COMPARATOR
Intervention: No biopsy during emergency gastroscopy
Number of subjects: 150
Study: 34332810

Group type: EXPERIMENTAL
Intervention: Stented distal urethroplasty (Group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Un-stented distal urethroplasty (Group B)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (stented and un-stented)
Number of subjects: 28
Study: 34252576

Group type: EXPERIMENTAL
Intervention: Transluminal injection of foam sclerotherapy (TLFS) with endovenous laser ablation (EVLA)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Ultrasound-guided foam sclerotherapy (UGFS) with endovenous laser ablation (EVLA)
Number of subjects: 197
Study: 32297754

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Computerized cognitive-behavioral therapy (CBT4CBT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard methadone treatment
Number of subjects: 120
Study: 34260595

Group type: EXPERIMENTAL
Intervention: Combination therapy with benazepril (10 mg/day) and valsartan (160 mg/day)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Benazepril (20 mg/day)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Valsartan (320 mg/day)
Number of subjects: 612
Study: 32249749

Group type: EXPERIMENTAL
Intervention: Super Skills for Life (SSL) intervention
Number of subjects: 67
Study: 34218992

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (Bup/Nal) treatment for 12 weeks
Number of subjects: 152

Group type: COMPARATOR
Intervention: Buprenorphine/naloxone (Bup/Nal) detoxification for up to 2 weeks
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Weekly drug counseling
Number of subjects: 152
Study: 34174706

Group type: EXPERIMENTAL
Intervention: Unguided low intensity cognitive behaviour therapy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 225
Study: 35886276

Group type: EXPERIMENTAL
Intervention: ATTACHTM parenting program
Number of subjects: 40
Study: 33031566

Group type: EXPERIMENTAL
Intervention: Obesity class I (BMI 30.0-34.9)
Number of subjects: 7189

Group type: EXPERIMENTAL
Intervention: Obesity classes II and III (BMI ≥35.0)
Number of subjects: 7189

Group type: EXPERIMENTAL
Intervention: Pre-obese women (BMI 25.0-29.9)
Number of subjects: 7189
Study: 32584630

Group type: EXPERIMENTAL
Intervention: Vandetanib
Number of subjects: 331
Study: 32827399

Group type: EXPERIMENTAL
Intervention: Halotherapy (HT)
Number of subjects: 0
Study: 33748852

Group type: EXPERIMENTAL
Intervention: AI‐ECG
Number of subjects: 258607

Group type: EXPERIMENTAL
Intervention: AI‐ECG with age and sex adjustment
Number of subjects: 258607

Group type: EXPERIMENTAL
Intervention: AI‐ECG in patients without hypertension
Number of subjects: 258607

Group type: EXPERIMENTAL
Intervention: False-positive AI‐ECG
Number of subjects: 258607
Study: 35032695

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 2912

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly (qw)
Number of subjects: 2912

Group type: EXPERIMENTAL
Intervention: Combined dupilumab (q2w and qw)
Number of subjects: 2912

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2912

Group type: EXPERIMENTAL
Intervention: Dupilumab q2w
Number of subjects: 2912

Group type: EXPERIMENTAL
Intervention: Dupilumab qw
Number of subjects: 2912
Study: 33130235

Group type: EXPERIMENTAL
Intervention: Verinurad (9mg) plus febuxostat (80mg) once daily for 24 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Matched placebo once daily for 24 weeks
Number of subjects: 60
Study: 32893745

Group type: EXPERIMENTAL
Intervention: Vitamin E and ginseng supplement (100 IU vitamin E, 67 mg Korean ginseng, and 40 mg Siberian ginseng)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 36476543

Group type: EXPERIMENTAL
Intervention: Vasopressin (40 IU) with initial epinephrine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo with initial epinephrine
Number of subjects: 148
Study: 32174307

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI in normal pregnancies
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diffusion-weighted MRI in complicated pregnancies
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subgroup analysis of dysfunctional placentas
Number of subjects: 40

Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 40
Study: 35275874

Group type: EXPERIMENTAL
Intervention: Facial proprioceptive neuromuscular facilitation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Connective tissue massage
Number of subjects: 40
Study: 34292203

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg per day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 32525954

Group type: EXPERIMENTAL
Intervention: Intervention group (received chickens at the start of the study)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (did not receive chickens until the end of the study)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 11
Study: 35437223

Group type: EXPERIMENTAL
Intervention: Oral magnesium chloride (MgCl2) for at least 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral magnesium chloride (MgCl2)
Number of subjects: 0
Study: 33950735

Group type: EXPERIMENTAL
Intervention: Community health worker-led intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35913424

Group type: EXPERIMENTAL
Intervention: Topical sialogogue spray containing 1% malic acid
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 52
Study: 32924913

Group type: EXPERIMENTAL
Intervention: Pragmatic intervention including systematic FC distress screening, privileged contact with an oncology nurse, and liaison with family physician for high distress FCs
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 109
Study: 32679405

Group type: EXPERIMENTAL
Intervention: Transoral surgery followed by low- or standard-dose, risk-adjusted post-operative therapy
Number of subjects: 120
Study: 32856547

Group type: EXPERIMENTAL
Intervention: 2-mg nicotine gum
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 4-mg nicotine gum
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 36394849

Group type: EXPERIMENTAL
Intervention: Avelumab plus talazoparib
Number of subjects: 223
Study: 33159007

Group type: EXPERIMENTAL
Intervention: QL1 technique
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: QL2 technique
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TOP QL3 technique
Number of subjects: 34
Study: 33371454

Group type: COMPARATOR
Intervention: High LF (600 mg/day)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Low LF (200 mg/day)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo (0 mg/day)
Number of subjects: 335
Study: 35578658

Group type: EXPERIMENTAL
Intervention: Favipiravir (FVP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 33836956

Group type: EXPERIMENTAL
Intervention: Spiritual care (SC) provided by pharmacists
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Avoidance of spiritual care (SC)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Education and training on spiritual care (SC)
Number of subjects: 251
Study: 35900605

Group type: EXPERIMENTAL
Intervention: Test gel containing propolis extract, nanovitamin C, and nanovitamin E applied 3 times/day for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control gel applied 3 times/day for 4 weeks
Number of subjects: 22
Study: 33782413

Group type: EXPERIMENTAL
Intervention: Oral oestroprogestogen contraceptive (OC)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low-dose combination of spironolactone-pioglitazone-metformin (SPIOMET)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Post-OC treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Post-SPIOMET treatment
Number of subjects: 58
Study: 32291813

Group type: EXPERIMENTAL
Intervention: 100 units of intradermal BTX‐A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combined emollients and topical mid‐potency steroid
Number of subjects: 30
Study: 36261447

Group type: EXPERIMENTAL
Intervention: NGF injection in masseter muscle
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isotonic saline injection in masseter muscle
Number of subjects: 28
Study: 32701874

Group type: EXPERIMENTAL
Intervention: Supplemented group (additional 5.1 MJ·d‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 32106832

Group type: EXPERIMENTAL
Intervention: Bupropion 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 30
Study: 35137448

Group type: COMPARATOR
Intervention: TM only group
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TM+BS group
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TM+CM group
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TM+BS+CM group
Number of subjects: 6
Study: 34237976

Group type: EXPERIMENTAL
Intervention: Family enteral nutrition (FEN)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Regular meals (control)
Number of subjects: 106
Study: 32155594

Group type: EXPERIMENTAL
Intervention: Spot-reduced IMPT plan
Number of subjects: 1

Group type: COMPARATOR
Intervention: Conventional clinical plan
Number of subjects: 1